| ID | 1282 |
| Name of the vaccine | SP306 (in Japan) |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 11 to 12 years |
| Description of the vaccine | Tdap vaccine. |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | Japan |
| Year of manufacture | 2015 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose of 0.1 mL. |
| Mechanism of action | Antitoxin concentrations greater than or equal to 0.1 IU/mL. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For tetanus and diphtheria. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02089347 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|